التفاصيل البيبلوغرافية
| العنوان: |
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers. |
| المؤلفون: |
Cavalcante, Ludimila, Deshmukh, Sachin Kumar, Ribeiro, Jennifer R., Carneiro, Benedito A., Dizon, Don S., Angara, Kartik, Mattox, Tyler, Wu, Sharon, Xiu, Joanne, Walker, Phillip, Oberley, Matthew, Nabhan, Chadi, Huang, Haojie, Antonarakis, Emmanuel S. |
| المصدر: |
JCO Precision Oncology; 9/7/2023, p1-23, 23p |
| مصطلحات موضوعية: |
PROSTATE cancer, ENDOMETRIAL cancer, GENE expression, MANN Whitney U Test, HORMONE receptors, GENETIC mutation |
| مستخلص: |
SPOP mutations drive opposing molecular and immune landscapes in prostate and endometrial cancers, suggesting tailored therapies PURPOSE: Recurrent gene mutations in speckle-type POZ protein (SPOP), the substrate-binding component of E3 ubiquitin ligase, are associated with tumor progression in prostate and endometrial cancers. Here, we characterized SPOP mutations in these cancers and explored their association with molecular and immune signatures and patient outcomes. METHODS: There were 7,398 prostate cancer and 19,188 endometrial cancer samples analyzed for clinical and molecular profiles at Caris Life Sciences. Overall survival (OS) was analyzed using Kaplan-Meier survival curves. Statistical significance was determined using chi-square and Mann-Whitney U tests, with P values adjusted for multiple comparisons. RESULTS: SPOP mutations were identified in 9.2% of prostate and 4.3% of endometrial cancers. Mutations clustered in the SPOP meprin and TRAF-C homology domain, with no significant overlap between cancer types. SPOP mutation was associated with differential comutation profiles and opposing tumor immune microenvironment signatures for each cancer, with greater immune infiltration in SPOP -mutated endometrial cancer. SPOP -mutated prostate and endometrial cancers displayed altered epigenetic gene expression, including opposite regulation of BRD2 transcripts. In SPOP -mutant prostate cancer, higher expression of androgen receptor–regulated transcripts and improved OS after treatment with hormonal agents were observed. In endometrial cancer, hormone receptor expression was significantly lower in SPOP -mutated tumors and differences in OS were highly dependent on the particular hotspot mutation and histologic subtype. CONCLUSION: These data indicate that SPOP mutations drive opposing molecular and immune landscapes in prostate and endometrial cancers—suggesting a loss-of-function mechanism in prostate cancer and gain-of-function mechanism in endometrial cancer—and provide a rationale for tailored therapeutic approaches. [ABSTRACT FROM AUTHOR] |
|
Copyright of JCO Precision Oncology is the property of American Society of Clinical Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
